Switzerland· 66979005
Amgevita
A adalimumab product containing adalimumabum, registered in Switzerland and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against BAG Spezialitätenliste (Switzerland) on
Informational only — not a medical device.
Where it is registered
Adalimumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AB04 (adalimumab), each read from that country’s own register.
- This record: Switzerland, from BAG Spezialitätenliste (Switzerland)
- 9 of them publish a price we can compare per daily dose
Adalimumab · ATC L04AB04
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of adalimumab costs, country by country.
Normalised to the WHO defined daily dose (2.9 mg), the median price runs from $0.015 in France to $36.00 in Switzerland — a ×2384 gap.
- Switzerland: $36.00 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Adalimumab · price per daily dose (2.9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$36.00
- FR France$0.015
The record
At a glance
BAG Spezialitätenliste (Switzerland)- Active substance
- adalimumabum
- Manufacturer
- —
- Country
- Switzerland (CH)
- ATC code
- L04AB04
- ATC class
- Adalimumab
- Defined daily dose
- 2.9 mg, P
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- BAG Spezialitätenliste (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680669790059Fertspr 1 StkCHF 218.2
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
429 interactions on record for adalimumab.
Graded by severity as the source publishes them — 286 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Adalimumab · interactions on record
429 records
- 286 severe
- 136 moderate
- 7 minor
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Adalimumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwedenAMGEVITA 20 mg/0,2 ml Injektionsvätska, lösning i förfylld sprutaAmgen Europe B.V.
- PolandHumiraAbbVie Deutschland GmbH & Co. KG
- CzechiaAMGEVITAAmgen Europe B.V., Breda
- FinlandAMGEVITAAmgen Europe B.V.
- United StatesAdalimumabSandoz Inc
- BelgiumAmgevita 20 mgAmgen Europe
- IcelandAmgevitaAmgen Europe B.V.*
- NetherlandsAmgevita 20 mg, oplossing voor injectie in een voorgevulde spuitAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Hukyndra, Humira
- Iceland · Amgevita, Amsparity
- Liechtenstein · Amsparity, Hefiya
- Norway · Amgevita, Amsparity
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of BAG Spezialitätenliste (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e0524800-406f-482f-8148-861f1215bb5f GET /v1/drugs/e0524800-406f-482f-8148-861f1215bb5f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "adalimumabum 20 mg",
"valid_from": "2024-06-01",
"limitations": "[{\"description\":\"Die 20 mg AMGEVITA-Dosisstärke ist ausschliesslich zur Anwendung bei Kindern und Jugendlichen vorgesehen.<br>\\n<br>\\n<b>Austausch Referenzpräparat/Biosimilar</b><br>\\nDie Behandlung mit AMGEVITA bedarf der Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes. Für die Behandlung mit AMGEVITA ist keine neue Kostengutsprache nötig, wenn in derselben Indikation bereits eine Kostengutsprache für das Referenzpräparat oder ein anderes Biosimilar besteht.<br>\\n<br>\\n<b>Aktive polyartikuläre juvenile idiopathische Arthritis bei Kindern und Jugendlichen im Alter von 4 bis 17 Jahren</b><br>\\nBehandlung mit AMGEVITA, wenn die vorausgegangene Standardtherapie mit krankheitsmodifizieren-den Antirheumatika (DMARDs) unzulänglich war.<br>\\n<br>\\n<b>Aktiver Morbus Crohn</b><br>\\nBehandlung pädiatrischer Patienten mit AMGEVITA, wenn die vorausgegangene konventionelle Therapie (z.B. mit Azathioprin, 6-Mercaptopurin oder Glukokortikoiden) unzulänglich war, sowie bei Patienten, die nicht mehr auf Infliximab ansprechen oder dieses nicht vertragen. Nach zwei Jahren ununterbrochener Therapie bedarf die Behandlung einer erneuten Kostengutsprache durch den Krankenversicherer nach vorgängiger Konsultation des Vertrauensarztes.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"points\":null,\"priceModel\":null,\"title\":null,\"validFrom\":\"2024-06-01\",\"validTo\":null}]",
"galenic_form": "Inj Lös 20 mg/0.2ml Fertspr",
"therapeutic_area": null,
"sl_inclusion_date": "2024-06-01",
"self_retention_pct": 10
}See everything about adalimumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.